213 related articles for article (PubMed ID: 20209617)
1. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
[TBL] [Abstract][Full Text] [Related]
2. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
3. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
4. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression.
Wimazal F; Baumgartner C; Sonneck K; Zauner C; Geissler P; Schur S; Samorapoompichit P; Müllauer L; Födinger M; Agis H; Sperr WR; Valent P
Eur J Clin Invest; 2008 Jun; 38(6):447-55. PubMed ID: 18445043
[TBL] [Abstract][Full Text] [Related]
5. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
6. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
7. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
Cordoba I; Gonzalez-Porras JR; Such E; Nomdedeu B; Luño E; de Paz R; Carbonell F; Vallespi T; Ardanaz M; Ramos F; Marco V; Bonanad S; Sanchez-Barba M; Costa D; Bernal T; Sanz GF; Cañizo MC
Leuk Res; 2012 Mar; 36(3):287-92. PubMed ID: 22133642
[TBL] [Abstract][Full Text] [Related]
8. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
Breccia M; Mancini M; Nanni M; D'Elia GM; Carmosino I; Latagliata R; Sarlo C; Mandelli F; Alimena G
Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
[TBL] [Abstract][Full Text] [Related]
12. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
13. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
16. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
17. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
Jacobs NL; Holtan SG; Porrata LF; Markovic SN; Tefferi A; Steensma DP
Am J Hematol; 2010 Mar; 85(3):160-3. PubMed ID: 20131304
[TBL] [Abstract][Full Text] [Related]
18. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
19. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Komrokji RS; Corrales-Yepez M; Al Ali N; Kharfan-Dabaja M; Padron E; Fields T; Lancet JE; List AF
Cancer; 2012 May; 118(10):2659-64. PubMed ID: 21956402
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
